15
Summary of Recommendations
Recommendation # Description
13.1
13.2
For patients with stage IV NSCLC and driver alterations in
NTRK
• In the first-line setting, entrectinib or larotrectinib may be
offered or standard treatment based on the ASCO/OH
non-driver mutation guideline may be offered (Moderate
recommendation: IC-L).
14.1
14.2
For patients with stage IV NSCLC and driver alterations in
NTRK
• In the second-line setting, if NTRK-targeted therapy was
given in the first-line setting, standard treatment based on
the ASCO/OH non-driver mutation guideline may be
offered (Moderate recommendation: IC-L).
• In the second-line setting, if NTRK-targeted therapy
was not given in the first-line setting, entrectinib or
larotrectinib may be offered (Moderate recommendation:
IC-L).
Unless otherwise noted, type of recommendation is evidence-based.
(cont'd)
